Literature DB >> 18438411

Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2.

Tatsukata Kawagoe1, Shintaro Sato, Kazufumi Matsushita, Hiroki Kato, Kosuke Matsui, Yutaro Kumagai, Tatsuya Saitoh, Taro Kawai, Osamu Takeuchi, Shizuo Akira.   

Abstract

Members of the IRAK family of kinases mediate Toll-like receptor (TLR) signaling. Here we show that IRAK2 was essential for sustaining TLR-induced expression of genes encoding cytokines and activation of the transcription factor NF-kappaB, despite the fact that IRAK2 was dispensable for activation of the initial signaling cascades. IRAK2 was activated 'downstream' of IRAK4, like IRAK1, and TLR-induced cytokine production was abrogated in the absence of both IRAK1 and IRAK2. Whereas the kinase activity of IRAK1 decreased within 1 h of TLR2 stimulation, coincident with IRAK1 degradation, the kinase activity of IRAK2 was sustained and peaked at 8 h after stimulation. Thus, IRAK2 is critical in late-phase TLR responses, and IRAK1 and IRAK2 are essential for the initial responses to TLR stimulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18438411     DOI: 10.1038/ni.1606

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  175 in total

Review 1.  Innate immune signaling in defense against intestinal microbes.

Authors:  Melissa A Kinnebrew; Eric G Pamer
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

2.  The dual functions of IL-1 receptor-associated kinase 2 in TLR9-mediated IFN and proinflammatory cytokine production.

Authors:  Youzhong Wan; Tae Whan Kim; Minjia Yu; Hao Zhou; Michifumi Yamashita; Zizhen Kang; Weiguo Yin; Jian-An Wang; James Thomas; Ganes C Sen; George R Stark; Xiaoxia Li
Journal:  J Immunol       Date:  2011-01-26       Impact factor: 5.422

Review 3.  Peli: a family of signal-responsive E3 ubiquitin ligases mediating TLR signaling and T-cell tolerance.

Authors:  Wei Jin; Mikyoung Chang; Shao-Cong Sun
Journal:  Cell Mol Immunol       Date:  2012-02-06       Impact factor: 11.530

Review 4.  Deciphering the complexity of Toll-like receptor signaling.

Authors:  Renato Ostuni; Ivan Zanoni; Francesca Granucci
Journal:  Cell Mol Life Sci       Date:  2010-07-31       Impact factor: 9.261

Review 5.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

6.  Structural biology: Immunity takes a heavy Toll.

Authors:  Steven A Wasserman
Journal:  Nature       Date:  2010-06-17       Impact factor: 49.962

7.  Combination therapy with VELCADE and tissue plasminogen activator is neuroprotective in aged rats after stroke and targets microRNA-146a and the toll-like receptor signaling pathway.

Authors:  Li Zhang; Michael Chopp; Xianshuang Liu; Hua Teng; Tao Tang; Haifa Kassis; Zheng Gang Zhang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-06-21       Impact factor: 8.311

8.  MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

Authors:  Lian Xu; Zachary R Hunter; Guang Yang; Yangsheng Zhou; Yang Cao; Xia Liu; Enrica Morra; Alessandra Trojani; Antonino Greco; Luca Arcaini; Marzia Varettoni; Maria Varettoni; Jennifer R Brown; Yu-Tzu Tai; Kenneth C Anderson; Nikhil C Munshi; Christopher J Patterson; Robert J Manning; Christina K Tripsas; Neal I Lindeman; Steven P Treon
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

Review 9.  MicroRNA-21 in the pathogenesis of acute kidney injury.

Authors:  Ya-Feng Li; Ying Jing; Jielu Hao; Nathan C Frankfort; Xiaoshuang Zhou; Bing Shen; Xinyan Liu; Lihua Wang; Rongshan Li
Journal:  Protein Cell       Date:  2013-11-10       Impact factor: 14.870

10.  Cutting edge: TLR signaling licenses IRAK1 for rapid activation of the NLRP3 inflammasome.

Authors:  Teresa Fernandes-Alnemri; Seokwon Kang; Connor Anderson; Junji Sagara; Katherine A Fitzgerald; Emad S Alnemri
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.